| Company* (Country; Symbol) |
Company | Type/Product Area | Terms/Details (Date) |
| CardioVascular BioTherapeutics Inc. (OTC BB: CVBTE) | Phillip Frey Jr. | Deal to form Cardio Derma Clinical Partners, a research and development partnership to conduct a wound healing clinical trial | Frey will fund a minimum of $1M and up to $5M of the clinical development of CVBT's wound healing drug candidate (4/24) |
| Osiris Therapeutics Inc. (OSIR) | NuVasive Inc. | Agreement to sell the Osteocel business to Nu-Vasive | Deal is worth $85M, $35M up front and up to $50M in milestone payments; in an agreement worth an additional $52M, Osiris will manufacture and supply Nu-Vasive with Osteocel for up to 18 months (5/9) |
| Senomyx Inc. (SNMX) | The Coca-Cola Co. | Expanded and extended collaborative research, development, commercialization and license agreement | The companies will continue to cooperate on activities related to the discovery, development and worldwide commercialization of new flavor ingredients (4/18) |
|
Notes: * Private companies are indicated with an asterisk. Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market.OTC BB = Over-the-Counter Bulletin Board. | |||
